Organ on a chip: A Commercialisation Report Card Trying to make an - - PowerPoint PPT Presentation

organ on a chip a commercialisation report card
SMART_READER_LITE
LIVE PREVIEW

Organ on a chip: A Commercialisation Report Card Trying to make an - - PowerPoint PPT Presentation

Organ on a chip: A Commercialisation Report Card Trying to make an objective assessment on the status of a new technology (and avoid the hype) Dr JM Wilkinson, Dr K Davidge Kirkstall Ltd. 06/12/2016 Content Challenges facing new


slide-1
SLIDE 1

06/12/2016

Organ on a chip: A Commercialisation Report Card

Trying to make an objective assessment on the status of a new technology (and avoid the hype)

Dr JM Wilkinson, Dr K Davidge Kirkstall Ltd.

slide-2
SLIDE 2

06/12/2016

Content

  • Challenges facing new technology introduction
  • Hype vs reality
  • Market need
  • Key factors for tracking success
  • Introducing a Report Card Format
  • Trial run with status of some key players
  • Recommendations for 2017
slide-3
SLIDE 3

06/12/2016

Some challenges for new technology

  • New technology must meet a market need
  • Winning grants is helpful but is not same as

winning customers

  • $ millions from VC’s does not guarantee success

(money does not change the laws of physics)

  • Early engagement with customers is essential
slide-4
SLIDE 4

Hype Cycle for Emerging Technologies

Gartner, Inc. Stamford, CT 06902 USA Organ on a chip has created high expectations

slide-5
SLIDE 5

High expectations:

  • rgan on a chip will provide a more effective way to test

safety and efficacy of new drugs

Slide from Dr. Barry Pallotta, Program Manager in DARPA’s Biological Technologies Office

There is a real market need ! Could be a $ multi-billion market by 2020

slide-6
SLIDE 6

06/12/2016

Market opportunities in Drug Discovery

Organ on chip goal is to replace HTS or animal

slide-7
SLIDE 7

Concept of Multi-Organ-Chip

Edinburgh 2014 Materne 7

slide-8
SLIDE 8

06/12/2016

A Multitude of Approaches

  • There is little standardisation
  • Players are mainly start-up companies commercialising

OOC prototypes developed in the universities

  • Mainly plastic materials
  • Different chamber and plate sizes

– Hurel, CN Bio, Mimetas use 96 well plate size – TissUse and Kirkstall use 24 well plate size – Wyss/Emulate has custom plates for each organ

  • Pneumatic, Peristaltic, & Syringe pumps as well as

gravity fed

  • In general the control systems are more complex than

the ‘chips’

slide-9
SLIDE 9

Organisation Chip Picture Controller Comments

Hurel (USA) MIT / CNBio (USA / UK) Mimetas (NL)

Chip is size of cigarette Pack, chamber is 24 well plate size Control system uses Pneumatic pumping Chip is 96 well plate format. Works in a standard incubator with rocker plate Chip has in-built microfluidic

  • pumps. Complex controller

needed. CNBio offer as a service Each organ chip is developed by a different group so not clear how they will interconnect. Technology only available as a service from Hurel who now focus on delivery of ready seeded 24 and 96 plates Chamber is 24 well plate format and in volume production with custom peristaltic pump

slide-10
SLIDE 10

06/12/2016

Key Requirements to replace animals

  • Biological
  • Physiologically relevant organoid models
  • Connected organoids
  • Long term culture /homeostasis
  • Practical
  • Easy to use and fast to set up
  • Robust/repeatable
  • No bubbles/blockages
  • Scale
  • 100’s animals/drug lead not 10,000’s as in HTS assays
  • Economical
  • Capital and consumable cost < animals
  • Replacing HTS will require much lower cost
slide-11
SLIDE 11

06/12/2016

Some Technical Challenges

  • Obtaining representative human cells
  • Media selection for co-culture of different cells
  • Seeding cells inside microstructured chambers
  • Getting adequate nutrient and oxygen to cells
  • Connecting multiple chambers and flowing

media

  • Getting enough biological material for an

accurate assay

slide-12
SLIDE 12

06/12/2016

Cells for human on a chip?

  • Animal cells may be easy to obtain and keep

alive – but they are not moving us forward

  • Human tumour derived cell lines are easy to

culture but are not representative of healthy tissue (basically cancer cells)

  • iPSC (Induced Pluripotent Stem Cells) look

promising but expensive and tough to grow

  • Human Donor Tissue is gold standard but

cryopreservation does compromise function

slide-13
SLIDE 13

Review Article : Organs-on-chips at the frontiers of drug discovery

Esch, Bahinski & Huh, Nature Reviews Drug Discovery 14, 248–260 (2015)

Cancer cells Cancer cells Cancer cells Vascular cells Heart cells Cancer cells Liver cells Vascular cells Cancer cells Cancer Cells Cancer cells Liver Cells Why so many tumour derived cancer cells? They are tough to kill!

slide-14
SLIDE 14

Given the right environment human cells can grow, differentiate and form organ-like structures

slide-15
SLIDE 15

Report Card Format : Technical Factors

Measure of progress Indicative Scores Physiologically relevant organoids Multiple organoids available Connected organoids Long term culture /homeostasis Easy to use / no bubbles / no leaks Robust/repeatable Scale to volume progress Economics

slide-16
SLIDE 16

Report Card Format : Technical Factors

Measure of progress Indicative Scores Physiologically relevant organoids

0 – 2D single cell type model 5 – 3D spheroid like model 9 – functional differentiated organoid

Multiple organoids available

+3 – liver +2 – cardiomyocytes + 2 –kidney +1 – other organs

Connected organoids

2 – manual transfer of conditioned media 6 - flow of media between chambers 9 - recirculating flow of media

Long term culture /homeostasis

1 – 2 to 3 days 5 – 28 days 10 – 90days+

Easy to use / no bubbles / no leaks

2 – in house only 5 – available for external use / licence 9 – already in use multiple sites

Robust/repeatable

2 – skilled postdoc researcher 5 – fully trained lab technician 9 – standard laboratory methods

Scale to volume progress

1 – single chambers 5 – 6 well chambers 7 – 24 well chambers

Economics

0 – no cost data available 3 – cost estimates available 7- on sale / cost match animals

slide-17
SLIDE 17

Report Card Format : Commercial Factors

Measure of progress Indicative Scores Organisation culture Market engagement Design for manufacture Ability to attract investment Sound business model Profitability TOTAL SCORE

slide-18
SLIDE 18

Report Card Format : Commercial Factors

Measure of progress Indicative Scores Organisation culture

2 - research laboratory 4 - research division in commercial organisation 8 - dedicated start up company

Market engagement

2 – industrial partners in research consortium 4 – sales to academics 6 – sales to industrial innovators 9 – sales to majority market

Design for manufacture

1 – in house prototyping 4 – industrial prototyping 6 – industrial preproduction 9 - volume manufacture process

Ability to attract investment

+3 - research grants only +4 - Venture Capital +3 - Sales revenue

Sound business model

0 - no business plan 5 - CRO Research model only 7 - products only 9 - products and service

Profitability

1 - burning investors capital 6 - break even 8 - profitable

TOTAL SCORE

slide-19
SLIDE 19

Report Card : Example Technical Scores

Measure of progress Indicative Scores W H C M T K Physiologically relevant organoids

0 – 2D single cell type model 5 – 3D spheroid like model 9 – functional differentiated organoid

4 4 3 3 6 6

Multiple organoids available

+2 – liver +2 – cardiomyocytes + 2 –kidney +1 – other organs

8 3 3 4 6 5

Connected organoids

2 – manual transfer of conditioned media 6 - flow of media between chambers 9 - recirculating flow of media

3 4 3 3 5 5

Long term culture /homeostasis

1 – 2 to 3 days 5 – 28 days 10 – 90days+

4 6 4 2 4 4

Easy to use / no bubbles / no leaks

2 – in house only 5 – available for licence 9 – already in use multiple sites

3 4 4 4 6 6

Robust/repeatable

2 – skilled postdoc researcher 5 – fully trained lab technician 9 – standard laboratory methods

3 4 4 3 5 6

Scale to volume progress

1 – single chambers 5 – 6 well chambers 7 – 24 well chambers

3 6 6 8 3 3

Economics

0 – no cost data available 3 – cost estimates available 7- on sale / cost match animals

3 5 3 5 3 5

slide-20
SLIDE 20

Report Card : Example Commercial Scores

Measure of progress Indicative Scores W H C M T K Organisation culture

2 - research laboratory 4 - research division in commercial organisation 8 - dedicated start up company

8 7 6 8 6 6

Market engagement

2 – industrial partners in research consortium 4 – sales to academics 6 – sales to industrial innovators 9 – sales to majority market

8 9 6 6 5 6

Design for manufacture

1 – in house prototyping 4 – industrial prototyping 6 – industrial preproduction 9 - volume manufacture process

4 5 5 6 4 6

Ability to attract investment

+3 - research grants only +4 - Venture Capital +3 - Sales revenue

9 6 8 8 7 6

Sound business model

0 - no business plan 5 - CRO Research model only 7 - products only 9 - products and service

8 7 7 7 5 7

Profitability

1 - burning investors capital 6 - break even 8 - profitable

4 5 6 2 2 6

slide-21
SLIDE 21

Overall Scorecard Result

Name Technical score Technical ranking Commercial score Commercial ranking Wyss 31 #5 41 #1 Hurel 36 #3 39 #2 CNBio 30 #6 38 #3 Mimetas 32 #4 37 #4= TissUse 38 #2 29 #6 Kirkstall 40 #1 37 #4=

Beware ! Trial Scores only – not really objective at this point

slide-22
SLIDE 22

25 27 29 31 33 35 37 39 41 43 25 27 29 31 33 35 37 39 41

Commercial score Technical score

Wyss Hurel CNBio Mimetas TissUse Kirkstall

Leading Commercialistion? Leading Technical Approach ?

slide-23
SLIDE 23

10 20 30 40 50 60 10 20 30 40 50 60 70 80

Commercial score Technical score

Wyss Hurel CNBio Mimetas TissUse Kirkstall

Commercial & Technical Success 2017 - 2020

slide-24
SLIDE 24

06/12/2016

Recommendations

  • Refine the scoring criteria
  • Add weighting factors? – which criteria are more

important

  • Use some independent assessors
  • Revisit scoring and ranking each year to track

progress Thanks for your attention!